Entry |
|
Name |
Enasidenib (USAN/INN) |
Formula |
C19H17F6N7O
|
Exact mass |
473.1399
|
Mol weight |
473.375
|
Structure |
|
Simcomp |
|
Remark |
Product (DG02837): | D11044<US> |
|
Efficacy |
Antineoplastic |
Target |
|
Pathway |
hsa01210 | 2-Oxocarboxylic acid metabolism |
|
Interaction |
|
Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XX Other antineoplastic agents
L01XX59 Enasidenib
D10901 Enasidenib (USAN/INN)
Target-based classification of drugs [BR:br08310]
Enzymes
Oxidoreductases (EC1)
Dehydrogenases
IDH2
D10901 Enasidenib (USAN/INN)
|
Other DBs |
|
KCF data |
ATOM 33
1 N5x N 12.7400 -18.2700
2 C8y C 12.7400 -19.6700
3 N5x N 13.9524 -20.3700
4 C8y C 15.1649 -19.6700
5 N5x N 15.1649 -18.2700
6 C8y C 13.9524 -17.5700
7 C8y C 13.9524 -16.1702
8 C8x C 15.1480 -15.4797
9 C8x C 15.1478 -14.0797
10 C8x C 13.9353 -13.3799
11 C8y C 12.7398 -14.0703
12 N5x N 12.7399 -15.4703
13 C1d C 11.5273 -13.3705
14 X F 10.3148 -12.6705
15 X F 10.8273 -14.5829
16 X F 12.2273 -12.1580
17 N1b N 16.3960 -20.3810
18 C8y C 17.6012 -19.6853
19 C8x C 18.7835 -20.3681
20 C8x C 19.9960 -19.6683
21 N5x N 19.9962 -18.2683
22 C8y C 18.8138 -17.5855
23 C8x C 17.6013 -18.2853
24 C1d C 18.8138 -16.1855
25 X F 18.8138 -14.7855
26 X F 17.4138 -16.1855
27 X F 20.2138 -16.1855
28 N1b N 11.5276 -20.3700
29 C1b C 10.3321 -19.6796
30 C1d C 9.1447 -20.3651
31 C1a C 7.9535 -19.6771
32 O1a O 9.1445 -21.7698
33 C1a C 7.9323 -21.0651
BOND 35
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 6 7 1
8 7 8 2
9 8 9 1
10 9 10 2
11 10 11 1
12 11 12 2
13 7 12 1
14 11 13 1
15 13 14 1
16 13 15 1
17 13 16 1
18 4 17 1
19 17 18 1
20 18 19 2
21 19 20 1
22 20 21 2
23 21 22 1
24 22 23 2
25 18 23 1
26 22 24 1
27 24 25 1
28 24 26 1
29 24 27 1
30 2 28 1
31 28 29 1
32 29 30 1
33 30 31 1
34 30 32 1
35 30 33 1
|